 |
|
|
| |
A RANDOMIZED TRIAL COMPARING RIBAVIRIN DOSE REDUCTION VERSUS ERYTHROPOIETIN FOR ANEMIA MANAGEMENT IN PREVIOUSLY UNTREATED PATIENTS WITH CHRONIC HEPATITIS C RECEIVING BOCEPREVIR PLUS PEGINTERFERON/RIBAVIRIN
|
| |
| |
Reported by Jules Levin
EASL 2012 Apr 18-22 Barcelona Spain
Fred Poordad,1 Eric J. Lawitz,2 K. Rajender Reddy,3 Nezam H. Afdhal,4 Christophe Hézode,5 Stefan Zeuzem,6 Samuel S. Lee,7 Jose Luis Calleja,8 Robert S. Brown, Jr,9 Antonio Craxi,10 Heiner Wedemeyer,11 Weiping Deng,12 Kenneth Koury,12 Navdeep Boparai,12* Lisa D. Pedicone,12 Margaret Burroughs,12 Janice
Wahl,12 Clifford A. Brass,12* Janice K. Albrecht,12* Mark S. Sulkowski13
1Cedars-Sinai Medical Center, Los Angeles, CA, USA; 2Alamo Medical Research, San Antonio, TX, USA; 3Division of Gastroenterology, University of Pennsylvania, Philadelphia, PA, USA; 4Beth Israel Deaconess Medical Center, Boston, MA, USA; 5Assistance Publique-Hopitaux de Paris, Henri Mondor Hospital, University of Paris, Paris, France;
6JW Goethe University Hospital, Frankfurt, Germany; 7University of Calgary, Calgary, Canada; 8Hospital U. Puerta de Hierro, Madrid, Spain; 9Columbia University College of Physicians & Surgeons, New York Presbyterian Hospital, New York, NY, USA; 10University of Palermo, Palermo, Italy; 11Hannover Medical School, Hannover, Germany; 12Merck Sharp & Dohme Corp., Whitehouse Station, NJ, USA; 13Johns Hopkins University School of Medicine, Baltimore, MD, USA
|
| |
|
|
|
|
|
